Potential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic prostate cancer
Prostate cancer is the second leading cause of cancer death in men and there is an urgent clinical need to improve its detection and treatment. The introduction of prostate-specific antigen (PSA) as a biomarker for prostate cancer several decades ago represented an important step forward in our abil...
Main Authors: | Jack Schalken, Siebren Dijkstra, Edwina Baskin-Bey, Inge van Oort |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2014-12-01
|
Series: | Therapeutic Advances in Urology |
Online Access: | https://doi.org/10.1177/1756287214545328 |
Similar Items
-
Personalized Management in Low-Risk Prostate Cancer: The Role of Biomarkers
by: Siebren Dijkstra, et al.
Published: (2012-01-01) -
Prostate Cancer Liquid Biopsy Biomarkers’ Clinical Utility in Diagnosis and Prognosis
by: Milena Matuszczak, et al.
Published: (2021-07-01) -
PCA3 and TMPRSS2-ERG: Promising Biomarkers in Prostate Cancer Diagnosis
by: Jack A. Schalken, et al.
Published: (2010-07-01) -
Hormone therapy in metastatic prostate cancer
by: Jebelameli P, et al.
Published: (1997-09-01) -
Non-invasive actionable biomarkers for metastatic prostate cancer
by: Jun Luo
Published: (2016-10-01)